OAKTREE CAPITAL MANAGEMENT LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
OAKTREE CAPITAL MANAGEMENT LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$7,195,058
-24.3%
7,295,000
-38.3%
0.10%
-16.8%
Q2 2023$9,508,858
+30.4%
11,824,000
+34.1%
0.12%
+54.3%
Q1 2023$7,289,292
+15.7%
8,816,000
+5.0%
0.08%
+22.7%
Q4 2022$6,300,448
+40.5%
8,395,000
+41.4%
0.07%
+34.7%
Q3 2022$4,484,0005,937,0000.05%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
PenderFund Capital Management Ltd. 9,295,000$12,5493.76%
Context Capital Management, LLC 23,076$22,6121.81%
Weiss Asset Management LP 16,160,000$15,847,9740.94%
Anson Funds Management LP 4,000,000$3,920,0000.79%
SYQUANT CAPITAL SAS 2,000,000$1,9610.77%
DG Capital Management, LLC 1,101,000$1,082,8340.59%
Skaana Management L.P. 2,000,000$1,957,6000.48%
AQR Arbitrage LLC 6,130,000$6,046,0190.27%
OAKTREE CAPITAL MANAGEMENT LP 7,295,000$7,195,0580.10%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$220,6580.04%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders